Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology
Disease Category: Depression (Major/Severe)

Trial Information

The Efficacy and Tolerability of Seroquel XR Combined with a Selective Serotonin Re-Uptake Inhibitor versus Seroquel XR Monotherapy in the Acute Treatment of Major Depressive Disorder with Psychotic Features

Have you been feeling down or depressed lately? If so, do you have unusual experiences where it seems that people are out to give you a hard time or to hurt you; do you hear, see, feel, smell, or taste things that other people do not experience?

If you have these symptoms, you may be suffering from a specific type of Major Depressive Disorder and may be eligible to participate in a treatment study at Massachusetts General Hospital. The purpose of this research study is to examine the effectiveness and safety of Seroquel when it is taken alone, compared to when it is taken in addition to an antidepressant, in the treatment of Major Depressive Disorder with Psychotic Features. You may be eligible if you are between the ages of 18-85 years.

The study involves 9 weekly visits to the DCRP. All subjects in this study will receive active treatment, and will be assigned by chance, like the flip of a coin, to take either Seroquel alone, or the combination of Seroquel and an antidepressant (Sertraline, Citalopram or Escitalopram).

For more information, please contact the research coordinator Rita at 617-724-9142.

Rita Seabrook
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114
Phone: 617-724-9142
EMail: rseabrook@partners.org

View Google Map

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.